Display options
Cite
Hattori H, Ishihara M. Feasibility of improving platelet-rich plasma therapy by using chitosan with high platelet activation ability. Exp Ther Med. 2017;13(3):1176-1180doi: 10.3892/etm.2017.4041.
Hattori, H., & Ishihara, M. (2017). Feasibility of improving platelet-rich plasma therapy by using chitosan with high platelet activation ability. Experimental and therapeutic medicine, 13(3), 1176-1180. https://doi.org/10.3892/etm.2017.4041
Hattori, Hidemi, and Ishihara, Masayuki. "Feasibility of improving platelet-rich plasma therapy by using chitosan with high platelet activation ability." Experimental and therapeutic medicine vol. 13,3 (2017): 1176-1180. doi: https://doi.org/10.3892/etm.2017.4041
Hattori H, Ishihara M. Feasibility of improving platelet-rich plasma therapy by using chitosan with high platelet activation ability. Exp Ther Med. 2017 Mar;13(3):1176-1180. doi: 10.3892/etm.2017.4041. Epub 2017 Jan 13. PMID: 28450960; PMCID: PMC5403699.
Copy Download .nbib Format: NLM
Share it on

Exp Ther Med. 2017 Mar;13(3):1176-1180. doi: 10.3892/etm.2017.4041. Epub 2017 Jan 13.

Feasibility of improving platelet-rich plasma therapy by using chitosan with high platelet activation ability.

Experimental and therapeutic medicine

Hidemi Hattori, Masayuki Ishihara

Affiliations

  1. Division of Biomedical Engineering, Research Institute, National Defense Medical College, Tokorozawa, Saitama 359-8513, Japan.
  2. Department of Biochemistry and Applied Biosciences, Faculty of Agriculture, University of Miyazaki, Miyazaki, Miyazaki 889-2192, Japan.

PMID: 28450960 PMCID: PMC5403699 DOI: 10.3892/etm.2017.4041

Abstract

Platelet-rich plasma (PRP) is blood plasma containing a high number of platelets that release growth factors for wound healing and tissue regeneration. In the present study, the feasibility of improving PRP therapy by using chitosan that exhibits high platelet activation ability was investigated. A total of 13 chitosan samples with different molecular weight (Mw) and degree of deacetylation (DDA) were individually added to blood samples of rats and the amount of growth factors, albumin and fibrinogen in plasma was measured. To examine the influence of plasma activated by chitosan on the proliferation of fibroblasts and adipose tissue-derived stromal cells (ASCs), the plasma was added to the culture medium of human fibroblasts and adipose tissue-derived stromal cells. Chitosan with a DDA of >75% increased the release of platelet factor 4 into the plasma. The amount of growth factors released into the plasma and platelet activation varied depending on the Mw and DDA, while albumin and fibrinogen were hardly affected. The proliferation rate was highest when using plasma activated by chitosan with a DDA of 75-85% and an Mw of 50,000-190,000 Da. These results suggested that the effectiveness of PRP therapy may be improved by using chitosan with a DDA of 75-85% and an Mw of 50,000-190,000 Da.

Keywords: cell proliferation; chitosan; deacetylation; growth factor; platelet activation; platelet-rich plasma

References

  1. Thromb Haemost. 2001 Sep;86(3):746-56 - PubMed
  2. Biomed Mater. 2015 Jan 22;10(1):015014 - PubMed
  3. Carbohydr Polym. 2013 Oct 15;98(1):665-76 - PubMed
  4. J Biomed Mater Res. 2000 Feb;49(2):225-32 - PubMed
  5. Wound Repair Regen. 2006 Nov-Dec;14(6):680-92 - PubMed
  6. Biomaterials. 2009 Feb;30(4):436-44 - PubMed
  7. Ann Biomed Eng. 2010 Dec;38(12):3724-32 - PubMed
  8. J Biomed Mater Res B Appl Biomater. 2013 Jan;101(1):28-35 - PubMed
  9. J Biol Regul Homeost Agents. 2012 Apr-Jun;26(2 Suppl 1):3S-22S - PubMed
  10. Atherosclerosis. 1988 Jul;72(1):77-82 - PubMed
  11. Ann Intern Med. 2013 Oct 15;159(8):532-42 - PubMed
  12. Biomed Mater. 2010 Oct;5(5):055001 - PubMed
  13. Am J Clin Pathol. 1977 Oct;68(4):505-7 - PubMed
  14. Surgery. 2001 Nov;130(5):844-50 - PubMed
  15. Adv Wound Care. 1997 Jul-Aug;10(4):33-8 - PubMed
  16. Arteriosclerosis. 1985 Jan-Feb;5(1):2-18 - PubMed
  17. Surg Today. 1992;22(4):333-8 - PubMed
  18. Cell Prolif. 2007 Apr;40(2):241-52 - PubMed
  19. Adv Skin Wound Care. 2007 Nov;20(11):591-600 - PubMed
  20. Blood. 1996 Sep 1;88(5):1525-41 - PubMed
  21. FEBS J. 2010 May;277(10):2208-14 - PubMed
  22. Platelets. 2000 May;11(3):151-60 - PubMed
  23. PLoS One. 2011;6(9):e24304 - PubMed
  24. J Immunol. 2013 Nov 15;191(10):5196-203 - PubMed
  25. Proc Natl Acad Sci U S A. 1986 Sep;83(17):6489-93 - PubMed
  26. Arterioscler Thromb Vasc Biol. 2007 Aug;27(8):1687-93 - PubMed
  27. Clin Oral Implants Res. 2006 Oct;17(5):572-8 - PubMed
  28. Nephrol Dial Transplant. 1987;2(4):280-1 - PubMed
  29. Biochim Biophys Acta. 1999 Aug 12;1451(1):163-72 - PubMed
  30. Arterioscler Thromb Vasc Biol. 2010 Dec;30(12):2341-9 - PubMed
  31. Blood. 1995 Apr 1;85(7):1796-804 - PubMed
  32. Int J Artif Organs. 1987 Jan;10(1):47-50 - PubMed
  33. J Oral Implantol. 2010;36(3):175-84 - PubMed
  34. J Trauma. 2006 Mar;60(3):655-8 - PubMed
  35. Cytotherapy. 2014 Feb;16(2):245-57 - PubMed
  36. Biochim Biophys Acta. 1972 Oct 25;279(3):456-74 - PubMed
  37. Thromb Res. 2010 Apr;125(4):292-6 - PubMed
  38. J Mater Sci Mater Med. 2008 Mar;19(3):1083-90 - PubMed
  39. Blood Rev. 2013 Mar;27(2):77-89 - PubMed
  40. Biotechnol Genet Eng Rev. 1996;13:383-420 - PubMed
  41. Eplasty. 2011;11:e38 - PubMed
  42. Anat Embryol (Berl). 1997 Jul;196(1):1-11 - PubMed

Publication Types